Do analysts prefer AQST or CUE?

Aquestive Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 110.40%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TLRY or CUE?

Tilray Brands presently has a consensus target price of $11.00, suggesting a potential upside of 151.14%. Given Tilray Brands' stronger consensus rating and higher possible upside, equities analysts clearly believe Tilray Brands is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray Brands 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer TLRY or CUE?

In the previous week, Tilray Brands had 18 more articles in the media than Cue Biopharma. MarketBeat recorded 26 mentions for Tilray Brands and 8 mentions for Cue Biopharma. Tilray Brands' average media sentiment score of 0.72 beat Cue Biopharma's score of 0.56 indicating that Tilray Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 12 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CUE or ZURA?

Zura Bio has a consensus price target of $10.75, indicating a potential upside of 112.45%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zura Bio 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Is CUE or ZURA more profitable?

Zura Bio has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Zura Bio's return on equity of -55.74% beat Cue Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Cue Biopharma -59.65% -98.30% -53.69% Zura Bio N/A -55.74% -48.07%

Does the media refer more to CUE or ZURA?

In the previous week, Cue Biopharma had 2 more articles in the media than Zura Bio. MarketBeat recorded 8 mentions for Cue Biopharma and 6 mentions for Zura Bio. Cue Biopharma's average media sentiment score of 0.56 beat Zura Bio's score of 0.54 indicating that Cue Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer OCGN or CUE?

Ocugen presently has a consensus target price of $9.50, suggesting a potential upside of 564.34%. Given Ocugen's stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, OCGN or CUE?

Cue Biopharma has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 109.77 -$67.85M -$0.24 N/A Cue Biopharma $27.47M 4.78 -$26.60M -$5.58 N/A

Is OCGN or CUE more profitable?

Ocugen has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% Cue Biopharma -59.65% -98.30% -53.69%

Does the media prefer OCGN or CUE?

In the previous week, Cue Biopharma had 4 more articles in the media than Ocugen. MarketBeat recorded 8 mentions for Cue Biopharma and 4 mentions for Ocugen. Cue Biopharma's average media sentiment score of 0.56 beat Ocugen's score of 0.47 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cue Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer STTK or CUE?

Shattuck Labs currently has a consensus price target of $11.00, suggesting a potential upside of 74.88%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shattuck Labs 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer STTK or CUE?

In the previous week, Cue Biopharma had 4 more articles in the media than Shattuck Labs. MarketBeat recorded 8 mentions for Cue Biopharma and 4 mentions for Shattuck Labs. Cue Biopharma's average media sentiment score of 0.56 beat Shattuck Labs' score of 0.45 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cue Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cue Biopharma (CUE) Competitors

$31.28 +0.36 (+1.16%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$31.36 +0.08 (+0.26%)

As of 08:43 AM Eastern

Compare

CUE vs. AQST, TLRY, ZURA, OCGN, and STTK

Should you buy Cue Biopharma stock or one of its competitors? MarketBeat compares Cue Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cue Biopharma include Aquestive Therapeutics (AQST), Tilray Brands (TLRY), Zura Bio (ZURA), Ocugen (OCGN), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry.

How does Cue Biopharma compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Aquestive Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market.

Cue Biopharma has a net margin of -59.65% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Cue Biopharma	-59.65%	-98.30%	-53.69%

Cue Biopharma has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.38	-$83.78M	-$0.61	N/A
Cue Biopharma	$27.47M	4.78	-$26.60M	-$5.58	N/A

Aquestive Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 110.40%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 14.6% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cue Biopharma had 7 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 8 mentions for Cue Biopharma and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.93 beat Cue Biopharma's score of 0.56 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aquestive Therapeutics	Positive
Cue Biopharma	Positive

Summary

Aquestive Therapeutics beats Cue Biopharma on 10 of the 17 factors compared between the two stocks.

How does Cue Biopharma compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Tilray Brands has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market.

Cue Biopharma has a net margin of -59.65% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Cue Biopharma	-59.65%	-98.30%	-53.69%

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 0.8% of Tilray Brands shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Tilray Brands had 18 more articles in the media than Cue Biopharma. MarketBeat recorded 26 mentions for Tilray Brands and 8 mentions for Cue Biopharma. Tilray Brands' average media sentiment score of 0.72 beat Cue Biopharma's score of 0.56 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	12 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cue Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cue Biopharma has lower revenue, but higher earnings than Tilray Brands. Cue Biopharma is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.62	-$2.19B	-$13.65	N/A
Cue Biopharma	$27.47M	4.78	-$26.60M	-$5.58	N/A

Tilray Brands presently has a consensus target price of $11.00, suggesting a potential upside of 151.14%. Given Tilray Brands' stronger consensus rating and higher possible upside, equities analysts clearly believe Tilray Brands is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tilray Brands beats Cue Biopharma on 9 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Zura Bio?

Cue Biopharma (NASDAQ:CUE) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Zura Bio has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Zura Bio's return on equity of -55.74% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Zura Bio	N/A	-55.74%	-48.07%

In the previous week, Cue Biopharma had 2 more articles in the media than Zura Bio. MarketBeat recorded 8 mentions for Cue Biopharma and 6 mentions for Zura Bio. Cue Biopharma's average media sentiment score of 0.56 beat Zura Bio's score of 0.54 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cue Biopharma has higher revenue and earnings than Zura Bio. Cue Biopharma is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.78	-$26.60M	-$5.58	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Zura Bio has a consensus price target of $10.75, indicating a potential upside of 112.45%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Cue Biopharma has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Summary

Zura Bio beats Cue Biopharma on 10 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Cue Biopharma has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	109.77	-$67.85M	-$0.24	N/A
Cue Biopharma	$27.47M	4.78	-$26.60M	-$5.58	N/A

Ocugen presently has a consensus target price of $9.50, suggesting a potential upside of 564.34%. Given Ocugen's stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ocugen has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
Cue Biopharma	-59.65%	-98.30%	-53.69%

10.3% of Ocugen shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cue Biopharma had 4 more articles in the media than Ocugen. MarketBeat recorded 8 mentions for Cue Biopharma and 4 mentions for Ocugen. Cue Biopharma's average media sentiment score of 0.56 beat Ocugen's score of 0.47 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocugen has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market.

Summary

Cue Biopharma beats Ocugen on 10 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 14.6% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Shattuck Labs has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Shattuck Labs' return on equity of -60.73% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Cue Biopharma	-59.65%	-98.30%	-53.69%

In the previous week, Cue Biopharma had 4 more articles in the media than Shattuck Labs. MarketBeat recorded 8 mentions for Cue Biopharma and 4 mentions for Shattuck Labs. Cue Biopharma's average media sentiment score of 0.56 beat Shattuck Labs' score of 0.45 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cue Biopharma has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	482.32	-$48.81M	-$0.63	N/A
Cue Biopharma	$27.47M	4.78	-$26.60M	-$5.58	N/A

Shattuck Labs has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market.

Shattuck Labs currently has a consensus price target of $11.00, suggesting a potential upside of 74.88%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Shattuck Labs and Cue Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Cue Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUE vs. The Competition

Export

Metric	Cue Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$129.88M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-5.60	20.98	26.94	24.38
Price / Sales	4.78	311.10	521.23	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	3.10	8.54	10.89	6.33
Net Income	-$26.60M	$23.83M	$3.59B	$331.02M
7 Day Performance	-11.51%	-2.77%	-1.53%	-0.33%
1 Month Performance	21.24%	5.85%	2.72%	-1.29%
1 Year Performance	-95.03%	52.15%	28.47%	21.30%

Cue Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUE Cue Biopharma	0.2955 of 5 stars	$31.28 +1.2%	N/A	-95.5%	$129.88M	$27.47M	N/A	60
AQST Aquestive Therapeutics	2.6644 of 5 stars	$4.10 +0.9%	$8.50 +107.6%	+0.2%	$513.80M	$44.54M	N/A	160
TLRY Tilray Brands	2.8221 of 5 stars	$4.39 -1.7%	$11.00 +150.9%	-33.3%	$512.24M	$821.31M	N/A	2,842	Analyst Forecast
ZURA Zura Bio	2.5934 of 5 stars	$5.19 +0.7%	$10.75 +107.3%	+289.2%	$492.90M	N/A	N/A	3	News Coverage Analyst Downgrade
OCGN Ocugen	2.3528 of 5 stars	$1.45 +2.5%	$9.50 +557.4%	+28.8%	$492.55M	$4.41M	N/A	80	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUE) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cue Biopharma (CUE) Competitors

CUE vs. AQST, TLRY, ZURA, OCGN, and STTK

How does Cue Biopharma compare to Aquestive Therapeutics?

Summary

How does Cue Biopharma compare to Tilray Brands?

Summary

How does Cue Biopharma compare to Zura Bio?

Summary

How does Cue Biopharma compare to Ocugen?

Summary

How does Cue Biopharma compare to Shattuck Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cue Biopharma (CUE) Competitors

CUE vs. AQST, TLRY, ZURA, OCGN, and STTK

How does Cue Biopharma compare to Aquestive Therapeutics?

Which has more volatility & risk, AQST or CUE?

Is AQST or CUE more profitable?

Which has higher earnings & valuation, AQST or CUE?

Do analysts prefer AQST or CUE?

Do institutionals & insiders believe in AQST or CUE?

Does the media favor AQST or CUE?

Summary

How does Cue Biopharma compare to Tilray Brands?

Which has more risk & volatility, TLRY or CUE?

Is TLRY or CUE more profitable?

Do institutionals and insiders have more ownership in TLRY or CUE?

Does the media prefer TLRY or CUE?

Which has higher valuation and earnings, TLRY or CUE?

Do analysts prefer TLRY or CUE?

Summary

How does Cue Biopharma compare to Zura Bio?

Is CUE or ZURA more profitable?

Does the media refer more to CUE or ZURA?

Do insiders and institutionals believe in CUE or ZURA?

Which has better valuation & earnings, CUE or ZURA?

Do analysts recommend CUE or ZURA?

Which has more volatility & risk, CUE or ZURA?

Summary

How does Cue Biopharma compare to Ocugen?

Which has stronger earnings and valuation, OCGN or CUE?

Do analysts prefer OCGN or CUE?

Is OCGN or CUE more profitable?

Do insiders and institutionals hold more shares of OCGN or CUE?

Does the media prefer OCGN or CUE?

Which has more risk & volatility, OCGN or CUE?

Summary

How does Cue Biopharma compare to Shattuck Labs?

Do institutionals & insiders hold more shares of STTK or CUE?

Is STTK or CUE more profitable?

Does the media prefer STTK or CUE?

Which has better valuation and earnings, STTK or CUE?

Which has more risk and volatility, STTK or CUE?

Do analysts prefer STTK or CUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools